Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes-Reference-Cited by-同舟云学术

Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

Published:2017-11-25 Issue:1 Volume:17 Page:
ISSN:1472-6963
Container-title:BMC Health Services Research
language:en
Short-container-title:BMC Health Serv Res

Author:

Matza Louis S.,Boye Kristina S.,Stewart Katie D.,Davies Evan W.,Paczkowski Rosirene

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Link

http://link.springer.com/content/pdf/10.1186/s12913-017-2648-7.pdf

Reference63 articles.

1. Palmer AJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26.

2. Ray JA, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin. 2007;23(3):609–22.

3. The Diabetes Prevention Program Research Group (DPPRG). Within-trial cost-effectiveness of lifestyle intervention or Metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26(9):2518–23.

4. Brazier JR, et al. Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press; 2007.

5. Feeny D. Preference-based measures: utility and quality-adjusted life years. In: Fayers P, Hays R, editors. Assessing quality of life in clinical trials. New York: Oxford University Press; 2005. p. 405–31.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health state utilities associated with weight loss: preferences of people with type 2 diabetes and obesity in Japan;Journal of Medical Economics;2024-03-11

2. Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States;Diabetes Therapy;2023-11-18

3. Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes;Journal of Patient-Reported Outcomes;2023-09-06

4. Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China;Patient Related Outcome Measures;2023-09

5. Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV;Quality of Life Research;2022-12-13